SCHEMBL25873156

SCHEMBL25873156

O=[N+]([O-])c1c(-c2ccc3ccccc3c2)c2ccccc2c2oc3ccccc3c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
HTT P42858 4/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HNF4A P41235 2/20 0.42
CYP3A4 P08684 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TNKS O95271 1/20 0.39
PARP1 P09874 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
CYP1A1 P04798 1/20 0.37
CYP1B1 Q16678 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25873155 0.81 CYP1A1 (0.38) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL17944007 0.77 CYP1A1 (0.40) MAPTMEN1KMT2AALDH1A1CYP3A4
SCHEMBL17944997 0.77 CYP1A1 (0.40) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL11573408 0.77 HNF4A (0.49) MAPTMEN1KMT2AHTTLMNA
SCHEMBL24341854 0.76 NPC1 (0.39) MAPTMEN1KMT2ACYP3A4NPC1
SCHEMBL17945113 0.76 CYP1A1 (0.39) MAPTMEN1KMT2AALDH1A1CYP3A4
SCHEMBL17944555 0.76 CYP1A1 (0.39) MAPTMEN1KMT2AALDH1A1CYP3A4
SCHEMBL24341584 0.76 CYP1A1 (0.39) MAPTMEN1KMT2ACYP3A4NPC1
SCHEMBL24340999 0.75 CYP1A1 (0.39) MAPTMEN1KMT2ACYP3A4NPC1
SCHEMBL19109838 0.75 NPC1 (0.38) MAPTMEN1KMT2ACYP3A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11706982-B2 Fused polycyclic compound, and preparation method and use thereof NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11706982-B2 Fused polycyclic compound, and preparation method and use thereof INF2, INTS9, PYM1 MAPT 955/4885MEN1 1402/4885KMT2A 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.